Latest Articles

Publication Date
Sterile abscess following intramuscular leuprolide acetate injection for endometriosis: A case report.

Sterile abscess formation after leuprolide acetate (LA) injection is rare and can lead to discomfort, scarring, and decreased treatment efficacy. Our objective is to highlight this rare side effect to …

Published: Nov. 17, 2025, midnight
Pharmacogenomic analysis of alarelin acetate-induced hepatotoxicity: a case report and literature review.

Alarelin acetate, a synthetic gonadotropin-releasing hormone (GnRH) analogue, is widely used to manage endometriosis and hormone-sensitive malignancies. Although its safety profile is generally favorable, we report the first documented case …

Published: Sept. 29, 2025, midnight
Leuprolide Acetate Market May See a Big Move | Major Giants- AbbVie, Mylan, Apotex - newstrail.com

Leuprolide Acetate Market May See a Big Move | Major Giants- AbbVie, Mylan, Apotex newstrail.com

Published: Sept. 13, 2025, 11:33 a.m.
Inguinal endometriosis: a rare entity of a common condition .

A woman in her mid-40s experienced a painful lump in the right groin area for 5 years, with exacerbation during menstruation, coughing and sneezing. Initial treatment with depot methylprednisolone acetate …

Published: Sept. 11, 2025, midnight
Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 as Demand for Hormone Therapy Accelerates – SNS Insider - SINA HONG KONG LIMITED

Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 as Demand for Hormone Therapy Accelerates – SNS Insider SINA HONG KONG LIMITED

Published: Sept. 2, 2025, 11:40 a.m.
Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 - GlobeNewswire

Leuprolide Acetate Market to Reach USD 4.43 Billion by 2032 GlobeNewswire

Published: Sept. 2, 2025, 10:32 a.m.
Gut Microbiota-Derived Acetate Ameliorates Endometriosis via JAK1/STAT3-Mediated M1 Macrophage Polarisation.

Endometriosis (EMs) is a common inflammatory disorder in women of reproductive age, severely impacting patients' quality of life and fertility. Current hormonal therapies offer limited efficacy, and surgical interventions often …

Published: Aug. 27, 2025, midnight
Factors Affecting Hormonal Therapy Ineffectiveness and Discontinuation due to Adverse Effects in Patients with Endometriosis-Associated Pain.

Endometriosis contributes to 5-21% of hospital admissions for pelvic pain. While hormonal therapies are pivotal in managing endometriosis-related pain, no single hormonal treatment suits all patients. We aimed to assess …

Published: Aug. 18, 2025, midnight
Relugolix in Monotherapy and Combined Therapy for the Treatment of Uterine Diseases and Its Effects on Bones: A Systematic Review.

Background: Uterine fibroids (UFs) and endometriosis are gynecological conditions that significantly increase morbidity among women of reproductive age. Relugolix, a novel gonadotropin-releasing hormone receptor antagonist, is approved in combined therapy …

Published: July 30, 2025, midnight
Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... - Medical Dialogues

Sun Pharma Gets CDSCO Panel Go-Ahead to Manufacture, Market Relugolix, Estradiol, Norethindrone Acetate... Medical Dialogues

Published: July 2, 2025, 11:31 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!